StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 7, 2026Score 9/30242% above fair value
$149.52+3.19 (+2.18%)

Close on Oct 30, 2026Market cap $368.89BP/E 119.6Yield 2.19%

Merck Pharmaceutical Sales by Quarter

Pharmaceutical Sales — Eastern Europe / Middle East / Africa ($M) ($M)

QuarterlyAnnual

Merck Pharmaceutical Sales: $408M in Q2 2026, down 9.5% from a year earlier.

Latest, Q2 2026
408
Period ended Jun 30, 2026
Change on a year earlier
-9.5%
451 in Q2 2025
History
30 quarters
Since Q1 2019
Sources
11
Documents cited below

Where the Q2 2026 figure comes from

“|| Eastern Europe/Middle East/Africa | 413 | 408 | 821 | 435 | 451 | 886 | 365 | 348 | 1,598 | -10 | -7”

Source: Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗

Reported in Form 8-K Supplemental Table 3c / 3b (Pharmaceutical Geographic Sales).

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedPharmaceutical Sales — Eastern Europe / Middle East / Africa ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026408-9.5%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026413-5.1%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2025Dec 31, 20253480.0%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q3 2025Sep 30, 2025365-8.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q2 2025Jun 30, 2025451+27.8%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q1 2025Mar 31, 2025435+10.1%Form 8-K (tm2621496d1_ex99-1.htm, filed 2026-08-04) ↗
Q4 2024Dec 31, 2024348+16.4%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q3 2024Sep 30, 2024400+32.9%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q2 2024Jun 30, 2024353-4.6%Form 8-K (tm2529620d1_ex99-1.htm, filed 2025-10-30) ↗
Q1 2024Mar 31, 2024395+3.7%Form 8-K (tm264564d1_ex99-1.htm, filed 2026-02-03) ↗
Q4 2023Dec 31, 2023299-6.6%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q3 2023Sep 30, 2023301-16.4%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q2 2023Jun 30, 2023370+9.1%Form 8-K (tm2426878d1_ex99-1.htm, filed 2024-10-31) ↗
Q1 2023Mar 31, 2023381-15.3%Form 8-K (tm255059d1_ex99-1.htm, filed 2025-02-04) ↗
Q4 2022Dec 31, 2022320+15.1%Form 8-K (tm244517d1_ex99-1.htm, filed 2024-02-01) ↗
Q3 2022Sep 30, 2022360-0.6%Form 8-K (tm2328962d1_ex99-1.htm, filed 2023-10-26) ↗

Breakdown

What makes up pharmaceutical Sales

Cite this data

StockData. (2026). Merck Pharmaceutical Sales ($M), quarterly Q1 2019–Q2 2026 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/pharma-geo-eemea

See every metric in the Merck KPI table. Data updated Oct 26, 2026.